Drug intelligence / Profile preview

ASP5502

Development stage: Unknown
Lead developer: Astellas Pharma Global Development, Inc.
Modality: Small Molecules
Administration: Oral

Overview

ASP5502 is an investigational small molecule drug developed by Astellas Pharma for the treatment of primary Sjögren's syndrome. It is a first-in-human, orally administered compound currently in Phase 1 clinical trials. The drug was designed using artificial intelligence to target immune homeostasis, with its mechanism of action believed to involve inhibition of STING (Stimulator of Interferon Genes), a key regulator in innate immunity and inflammation. The primary indication under investigation is primary Sjögren's syndrome, an autoimmune disease characterized by dry mouth and eyes due to lymphocytic infiltration of exocrine glands.

Other names: ASP-5502ASP5502ASP 5502

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on ASP5502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASP5502.

Explore the full profile